Sinalização PI3K/Akt/mTOR
Os inibidores da sinalização PI3K/Akt/mTOR são compostos que têm como alvo as vias da fosfoinositídeo 3-quinase (PI3K), da quinase Akt e do alvo da rapamicina em mamíferos (mTOR). Essas vias são reguladores críticos do crescimento celular, sobrevivência, metabolismo e autofagia, tornando-os alvos-chave na pesquisa de câncer e distúrbios metabólicos. A inibição dessas vias pode ajudar a controlar o crescimento e a proliferação tumoral, oferecendo estratégias terapêuticas potenciais para vários tipos de câncer e outras doenças caracterizadas por sinalização celular desregulada. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de alta qualidade de PI3K/Akt/mTOR para apoiar sua pesquisa em oncologia, sinalização celular e doenças metabólicas.
Subcategorias de "Sinalização PI3K/Akt/mTOR"
- AMPK(158 produtos)
- ATM/ATR(71 produtos)
- DNA-PK(51 produtos)
- EGFR(572 produtos)
- MELK(7 produtos)
- PDK(9 produtos)
- PI3K(242 produtos)
- S6 Quinase(9 produtos)
- gsk-3(112 produtos)
- mTOR(144 produtos)
Exibir 2 mais subcategorias
Foram encontrados 1038 produtos de "Sinalização PI3K/Akt/mTOR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
AG-1478 hydrochloride
CAS:<p>AG1478 HCl is an epidermal growth factor receptor protein inhibitor.</p>Fórmula:C16H15Cl2N3O2Cor e Forma:SolidPeso molecular:352.21Phosphatidylinositol 4,5-bisphosphate
CAS:<p>Phosphatidylinositol 4,5-bisphosphate, a cell membrane phospholipid, is a PLC and PI3K substrate and a messenger.</p>Fórmula:C47H85O19P3Cor e Forma:SolidPeso molecular:1047.09Lumretuzumab
CAS:<p>Lumretuzumab (RG-7116) is a humanized anti-HER3 monoclonal antibody with antitumor activity.</p>Pureza:95.3% (SDS-PAGE); 96.4% (SEC-HPLC) - 95.3% (SDS-PAGE); 96.4% (SEC-HPLC)Cor e Forma:LiquidEGFR-IN-95
<p>EGFR-IN-95 is a derivative of 2,4-diaminonicotinamide. It effectively inhibits the activity of EGFRdel19/T790M/C797S and L858R/T790M/C797S.</p>Fórmula:C23H28F2N8O3SPeso molecular:534.19731GSK-3β inhibitor 24
<p>GSK-3β inhibitor24 (Compound 41) is a potent GSK-3β inhibitor with an IC50 of 0.22 nM. It increases GSK-3β phosphorylation at the Ser9 site in a dose-dependent manner and inhibits tau protein hyperphosphorylation by reducing the abundance of p-tau-Ser396. The compound upregulates β-catenin and neurogenesis-related markers (GAP43 and MAP-2), demonstrating significant anti-Alzheimer's disease (AD) activity.</p>Fórmula:C26H18N4O3Cor e Forma:SolidPeso molecular:434.446AMX-818
<p>AMX-818 is a conditionally activated, masked T cell engager (TCE) that targets HER2. It demonstrates potent T cell cytotoxicity against HER2-positive tumor cell lines and can induce tumor regression in vivo. AMX-818 holds promise for research into HER2-positive solid tumors.</p>Cor e Forma:Odour LiquidEGFR-IN-162
<p>EGFR-IN-162 (compound 20) is an effective EGFR inhibitor that enhances both early and late apoptosis (EGFR) as well as necrosis (necrosis). It shows potential for use in breast cancer research.</p>Fórmula:C27H31N3O2Cor e Forma:SolidPeso molecular:429.24163GSK3β/mTOR modulator 1
<p>GSK3β/mTOR modulator 1 (derivative 2) is an agent that modulates the GSK3β/mTOR signaling pathway. It is applicable in research related to acute lung injury (ALI) and inflammation.</p>Fórmula:C19H28O5Cor e Forma:SolidPeso molecular:336.19367EGFR-IN-116
<p>EGFR-IN-116 (compound 14D) is an antineoplastic agent. It exhibits an IC50 value of 0.103 μM for EGFR, 0.069 μM for VEGFR-2, and 19.74 μM for Topo II.</p>Fórmula:C26H22N6O2SPeso molecular:482.1525mTOR inhibitor WYE-28
CAS:<p>Compound 28 (mTOR inhibitor WYE-28) is a selective inhibitor of mTOR (IC50=0.08 nM). Also inhibits PI3Kα (IC50 6 nM).</p>Fórmula:C30H34N8O5Cor e Forma:SolidPeso molecular:586.6532B-(SP)
CAS:<p>Selective phosphopeptide substrate for glycogen synthase kinase-3 (GSK-3)</p>Fórmula:C71H123N26O29PPureza:98%Cor e Forma:SolidPeso molecular:1835.87RMC-4627
CAS:<p>RMC-4627 is a selective mTORC1 inhibitor that activates 4EBP1 and inhibits tumor growth.</p>Fórmula:C93H141N11O23Cor e Forma:SolidPeso molecular:1781.17PROTAC EGFR degrader 2
<p>Potent PROTAC EGFR degrader 2; IC50: 4.0 nM, DC50: 36.51 nM; inhibits cell growth; for NTR-responsive synthesis.</p>Fórmula:C58H72ClFN12O8SCor e Forma:SolidPeso molecular:1151.78GSK251
CAS:<p>GSK251 is a novel, orally bioavailable inhibitor of PI3Kδ, exhibiting high potency and selectivity, with a unique binding mode.</p>Fórmula:C29H37FN6O4SPureza:99.8%Cor e Forma:SolidPeso molecular:584.71Pertuzumab
CAS:<p>Pertuzumab (anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2</p>Pureza:98.00%Cor e Forma:LiquidPeso molecular:148 kDaDSPE-PEG1000-GE11
<p>DSPE-PEG1000-GE11 is a PEG compound made up of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells overexpressing EGFR. DSPE-PEG1000-GE11 serves a role in drug delivery.</p>Cor e Forma:Odour SolidPI3K-IN-57
<p>PI3K-IN-57 (Compound 4a) is a PI3K inhibitor that shows strong inhibitory effects on the proliferation of HeLa tumor ectopic xenografts in vivo. It holds promise for anticancer agent research.</p>Cor e Forma:Odour SolidEGFR-IN-140
<p>EGFR-IN-140 (Compound 31) is an inhibitor of EGFR, effectively targeting both wild-type EGFR and the EGFRL858R/T790M/C797S mutant, with Ki values of 0.95 nM and 2.1 nM, respectively. Additionally, it inhibits EGFRdel19/T790M/C797S in Ba/F3 cells with an IC50 of 56.9 nM and demonstrates antitumor activity in mouse models.</p>Fórmula:C27H37FN8O2Cor e Forma:SolidPeso molecular:524.633Duvelisib (R enantiomer) hydrochloride
<p>Duvelisib (R enantiomer) hydrochloride (INK1197 R enantiomer HCl) is a PI3K inhibitor.</p>Fórmula:C22H18Cl2N6OPureza:99.88% - >99.99%Cor e Forma:SoildPeso molecular:453.32MS9427
CAS:<p>MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.</p>Fórmula:C48H58ClFN8O12Cor e Forma:SolidPeso molecular:993.47
